Impact of longitudinal exposure to mycophenolic acid on acute rejection in renal-transplant recipients using a joint modeling approach

Pharmacological Research

Volumn 72, Issue , 2013, Pages 52-60

  Daher Abdi, Z ^a,c   Essig, M ^a,b,c   Rizopoulos, D ^d   Le Meur, Y ^e   Premaud A ^a,c   Woillard, J B ^a,c   Rerolle J P ^a,b   Marquet, P ^a,b,c   Rousseau, A ^a,c  

^a INSERM   (France)

^b LIMOGES UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY OF LIMOGES   (France)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e BREST UNIVERSITY HOSPITAL   (France)

Author keywords

Acute rejection; Joint modeling; Longitudinal exposure; Mycophenolic acid; Renal transplant recipients; ROC thresholds

Indexed keywords

ANTICOAGULANT AGENT; BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN; DACLIZUMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; AREA UNDER THE CURVE; ARTICLE; BOOTSTRAPPING; DISEASE FREE SURVIVAL; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EXPOSURE; DRUG MONITORING; FOLLOW UP; GRAFT RECIPIENT; HUMAN; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; MULTICENTER STUDY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); VALIDATION PROCESS;

ADULT; AGE FACTORS; AGED; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MIDDLE AGED; MODELS, BIOLOGICAL; MYCOPHENOLIC ACID; ROC CURVE;

EID: 84876972565     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2013.03.009     Document Type: Article

References (43)

1. T. Van Gelder Therapeutic drug monitoring for mycophenolic acid is value for (little) money Clinical Pharmacology and Therapeutics 90 2 2011 203 204
2. R. Byrne, S.E. Yost, and B. Kaplan Mycophenolate mofetil monitoring: is there evidence that it can improve outcomes? Clinical Pharmacology and Therapeutics 90 2 2011 204 206
3. P.I. Pillans, R.J. Rigby, P. Kubler, C. Willis, P. Salm, and S.E. Tett A retrospective analysis of mycophenolic acid and cyclosporin concentrations with acute rejection in renal transplant recipients Clinical Biochemistry 34 1 2001 77 81
4. M. Okamoto, Y. Wakabayashi, A. Higuchi, Y. Kadotani, S. Ogino, and H. Ushigome Therapeutic drug monitoring of mycophenolic acid in renal transplant recipients Transplantation Proceedings 37 2 2005 859 860
5. T. Pawinski, M. Durlik, I. Szlaska, A. Urbanowicz, J. Majchrnak, and B. Gralak Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant Journal of Clinical Pharmacy and Therapeutics 31 1 2006 27 34
6. S. Satoh, H. Tada, M. Murakami, N. Tsuchiya, T. Inoue, and H. Togashi The influence of mycophenolate mofetil versus azathioprine and mycophenolic acid pharmacokinetics on the incidence of acute rejection and infectious complications after renal transplantation Transplantation Proceedings 37 4 2005 1751 1753
7. B.A. Atcheson, P.J. Taylor, D.W. Mudge, D.W. Johnson, C.M. Hawley, and S.B. Campbell Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant British Journal of Clinical Pharmacology 59 3 2005 271 280
8. D.R.J. Kuypers, K. Claes, P. Evenepoel, B. Maes, and Y. Vanrenterghem Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients Clinical Pharmacology and Therapeutics 75 5 2004 434 447
9. K. Benson, and A.J. Hartz A comparison of observational studies and randomized, controlled trials New England Journal of Medicine 342 25 2000 1878 1886
10. J.L. Meakins Innovation in surgery: the rules of evidence American Journal of Surgery 183 4 2002 399 405
11. T. Van Gelder, L.B. Hilbrands, Y. Vanrenterghem, W. Weimar, J.W. De Fijter, and J.P. Squifflet A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation Transplantation 68 2 1999 261 266
12. Y. Le Meur, M. Büchler, A. Thierry, S. Caillard, F. Villemain, and S. Lavaud Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation American Journal of Transplantation 7 11 2007 2496 2503
13. T. Van Gelder, H.T. Silva, J.W. De Fijter, K. Budde, D. Kuypers, and G. Tyden Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial Transplantation 86 8 2008 1043 1051
14. T. Van Gelder, H. Tedesco Silva, J.W. De Fijter, K. Budde, D. Kuypers, and W. Arns Renal transplant patients at high risk of acute rejection benefit from adequate exposure to mycophenolic acid Transplantation 89 5 2010 595 599
15. A. Prémaud, Y. Le Meur, J. Debord, J.-C. Szelag, A. Rousseau, and G. Hoizey Maximum a posteriori bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods Therapeutic Drug Monitoring 27 3 2005 354 361
16. Y. Le Meur, A. Thierry, F. Glowacki, J.-P. Rerolle, V. Garrigue, and N. Ouali Early steroid withdrawal and optimization of mycophenolic acid exposure in kidney transplant recipients receiving mycophenolate mofetil Transplantation 92 11 2011 1244 1251
17. A. Prémaud, A. Rousseau, Y. Le Meur, N. Venisse, C. Loichot, and A. Turcant Feasibility of, and critical paths for mycophenolate mofetil Bayesian dose adjustment: pharmacological re-appraisal of a concentration-controlled versus fixed-dose trial in renal transplant recipients Pharmacological Research 61 2 2010 167 174
18. Y. Le Meur, R. Borrows, M.D. Pescovitz, K. Budde, J. Grinyo, and R. Bloom Therapeutic drug monitoring of mycophenolates in kidney transplantation: report of The Transplantation Society consensus meeting Transplantation Reviews (Orlando) 25 2 2011 58 64
19. D.R.J. Kuypers, Y. Le Meur, M. Cantarovich, M.J. Tredger, S.E. Tett, and D. Cattaneo Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation Clinical Journal of the American Society of Nephrology 5 2 2010 341 358
20. L.M. Shaw, H.W. Sollinger, P. Halloran, R.E. Morris, R.W. Yatscoff, and J. Ransom Mycophenolate mofetil: a report of the consensus panel Therapeutic Drug Monitoring 17 6 1995 690 699
21. F. Saint-Marcoux, S. Vandierdonck, A. Prémaud, J. Debord, A. Rousseau, and P. Marquet Large scale analysis of routine dose adjustments of mycophenolate mofetil based on global exposure in renal transplant patients Therapeutic Drug Monitoring 33 3 2011 285 294
22. D. Rizopoulos JM: an R package for the joint modeling of longitudinal and time-to-event data Journal of Statistical Software 35 2010 1 33
23. A.A. Tsiatis, and M. Davidian Joint modeling of longitudinal and time-to-event data: an overview Statistica Sinica 14 2004 809 834
24. M. Yu, N.J. Law, J.M.G. Taylor, and H.M. Sandler Joint longitudinal-survival-cure models and their application to prostate cancer Statistica Sinica 14 2004 835 862
25. H. Jacqmin-Gadda, R. Thiébaut, and J.-F. Dartigues Joint modeling of quantitative longitudinal data and censored survival time Revue d Epidemiologie et de Sante Publique 52 6 2004 502 510
26. Z. Zhou, J. Shen, Y. Hong, S. Kaul, M. Pfister, and A. Roy Time-varying belatacept exposure and its relationship to efficacy/safety responses in kidney-transplant recipients Clinical Pharmacology and Therapeutics 92 2 2012 251 257
27. D. Rizopoulos Dynamic predictions and prospective accuracy in joint models for longitudinal and time-to-event data Biometrics 67 3 2011 819 829
28. K. Solez, R.B. Colvin, L.C. Racusen, M. Haas, B. Sis, and M. Mengel Banff 07 classification of renal allograft pathology: updates and future directions American Journal of Transplantation 8 4 2008 753 760
29. P. Hougaard Fundamentals of survival data Biometrics 55 1 1999 13 22
30. D. Rizopoulos, G. Verbeke, and G. Molenberghs Multiple-imputation-based residuals and diagnostic plots for joint models of longitudinal and survival outcomes Biometrics 66 1 2010 20 29
31. T. Pawinski, M. Durlik, I. Szlaska, A. Urbanowicz, J. Ostrowska, and B. Gralak The weight of pharmacokinetic parameters for mycophenolic acid in prediction of rejection outcome: the receiver operating characteristic curve analysis Transplantation Proceedings 38 1 2006 86 89
32. V.W. Armstrong, M. Shipkova, E. Schütz, L. Weber, B. Tönshoff, and M. Oellerich Monitoring of mycophenolic acid in pediatric renal transplant recipients Transplantation Proceedings 33 1-2 2001 1040 1043
33. L.M. Shaw, M. Korecka, R. Venkataramanan, L. Goldberg, R. Bloom, and K.L. Brayman Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies American Journal of Transplantation 3 5 2003 534 542
34. R.M. Van Hest, T. Van Gelder, R. Bouw, T. Goggin, R. Gordon, and R.D. Mamelok Time-dependent clearance of mycophenolic acid in renal transplant recipients British Journal of Clinical Pharmacology 63 6 2007 741 752
35. G. Levy, E. Thervet, J. Lake, and K. Uchida Patient management by Neoral C(2) monitoring: an international consensus statement Transplantation 73 9 Suppl. 2002 S12 S18
36. F.G. Cosio, H. Amer, J.P. Grande, T.S. Larson, M.D. Stegall, and M.D. Griffin Comparison of low versus high tacrolimus levels in kidney transplantation: assessment of efficacy by protocol biopsies Transplantation 83 4 2007 411 416
37. A.C. Webster, R.C. Woodroffe, R.S. Taylor, J.R. Chapman, and J.C. Craig Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data BMJ 331 2005 810 821
38. Y.-J. Lee, B. Kim, J.E. Lee, Y.-G. Kim, D.J. Kim, and S.-J. Kim Randomized trial of cyclosporine and tacrolimus therapy with steroid withdrawal in living-donor renal transplantation: 5-year follow-up Transplant International 23 2 2010 147 154
39. S. Sandrini, N. Aslam, R. Tardanico, G. Setti, N. Bossini, and F. Valerio Tacrolimus versus cyclosporine for early steroid withdrawal after renal transplantation Journal of Nephrology 25 1 2012 43 49
40. T. Van Gelder, H.T. Silva, H. De Fijter, K. Budde, D. Kuypers, and R.D. Mamelok How delayed graft function impacts exposure to mycophenolic acid in patients after renal transplantation Therapeutic Drug Monitoring 33 2 2011 155 164
41. J. Karczewski, M. Karczewski, and K. Wiktorowicz Preliminary study evaluating the risk factors of kidney acute rejection Central European Journal of Immunology 36 2011 233 236
42. E.S. Woodle, R.R. Alloway, J.F. Buell, J.W. Alexander, R. Munda, and P. Roy-Chaudhury Multivariate analysis of risk factors for acute rejection in early corticosteroid cessation regimens under modern immunosuppression American Journal of Transplantation 5 11 2005 2740 2744
43. O. Gensburger, R.H.N. Van Schaik, N. Picard, Y. Le Meur, A. Rousseau, and J.-B. Woillard Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil Pharmacogenet Genomics 20 9 2010 537 543